Evidence map›Paper›PMID 40321618›Full record

ArticleNeuro-oncology advances

Nuclear NAD

Jiaqi Liu, Yi Zhu, Tijana Canic, Zoraida Diaz-Perez, Sakir Humayun Gultekin, R Grace Zhai

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jiaqi LiuDepartment of Neurology, University of Chicago Biological Sciences, Chicago, Illinois, IL 60637, USA.ORCID https://orcid.org/0000-0001-6526-8655
Yi ZhuDepartment of Molecular and Cellular Pharmacology, University of Miami Miller School of Medicine, Miami, Florida, FL 33136, USA.
Tijana CanicDepartment of Molecular and Cellular Pharmacology, University of Miami Miller School of Medicine, Miami, Florida, FL 33136, USA.
Zoraida Diaz-PerezDepartment of Molecular and Cellular Pharmacology, University of Miami Miller School of Medicine, Miami, Florida, FL 33136, USA.
Sakir Humayun GultekinNeuropathology Division and The Translational Research Histology, University of Miami Miller School of Medicine, Miami, Florida, FL 33136, USA.ORCID https://orcid.org/0000-0002-4717-0408
R Grace ZhaiDepartment of Neurology, University of Chicago Biological Sciences, Chicago, Illinois, IL 60637, USA.ORCID https://orcid.org/0000-0002-7599-1430

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Glioma is a malignant primary brain tumor with a poor prognosis and short survival. NAD Methods: We carried out high-resolution immunohistochemical analyses on glioma tissue samples from 19 patients to analyze the expression of NAD Results: In low-grade glioma and glioblastoma, a higher transcription level of NMNAT1 is correlated with poorer disease-free survival. Samples of high-grade gliomas contained a higher percentage of glial cells enriched with NMNAT1 protein. We identified a specific correlation between nuclear NMNAT1 protein level with nuclear atypia. Mechanistic studies in human glioma cell lines and in vivo Conclusions: Our study uncovers a novel functional connection between the NAD

Indexed as

DrosophilaEGFRglioblastomalamin A/CNAD+

Identifiers

PMID40321618
PMCPMC12048879

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.